GDF-11
Growth Differentiation Factor 11
GDF-11 (Growth Differentiation Factor 11) is a TGF-beta superfamily member that has attracted significant research interest as a potential 'rejuvenation factor' following parabiosis studies suggesting circulating GDF-11 levels decline with age. It is primarily investigated for its roles in neural progenitor cell regulation, cardiac and skeletal muscle remodeling, and systemic aging biology, though its precise role as a pro-youthful versus pro-aging factor remains actively debated in the literature.
Mechanism of Action
GDF-11 signals through activin receptor type II (ActRIIA/ActRIIB) and their co-receptors ALK4/ALK5/ALK7, activating SMAD2/3 phosphorylation and downstream transcriptional regulation of genes involved in cell differentiation, proliferation, and senescence. It modulates myostatin-related pathways, influences neurogenesis in the olfactory epithelium and subventricular zone, and regulates cardiomyocyte hypertrophy, though whether exogenous GDF-11 supplementation recapitulates the effects observed in parabiosis models in humans remains unproven.
Evidence by Health Goal(17 goals)
Dosing Protocols
Morning, subcutaneous injection into abdominal or deltoid region
Cycle: 4-8 weeks on, 4 weeks off
Dosing protocols are entirely experimental with no established human clinical guidelines. Doses used in rodent studies (typically 0.1mg/kg) do not translate directly to human dosing. Research-grade only; no approved human formulations exist. Reconstitute lyophilized powder with bacteriostatic water per vendor instructions.
Safety & Side Effects
GDF-11 has no established safety profile in humans as it has not completed clinical trials, and existing data is largely from murine studies that have produced conflicting results - some showing rejuvenating cardiac effects while others demonstrate pro-aging or muscle-wasting outcomes. Self-administration carries substantial unknown risks including unintended effects on cardiac structure, hematopoiesis, and tissue differentiation; it is classified as a research chemical and is not approved for human therapeutic use in any jurisdiction.
Possible Side Effects
- !Injection site irritation, redness, or mild swelling
- !Muscle weakness or fatigue at higher doses due to anti-hypertrophic myostatin-like activity
- !Potential suppression of erythropoiesis leading to reduced red blood cell counts with prolonged use
- !Nausea or gastrointestinal discomfort, particularly with incorrect reconstitution or higher doses
- !Headache reported anecdotally in self-experimenting users
- !Theoretical immunomodulatory effects including altered inflammatory response
- !Potential cardiovascular remodeling effects with unknown long-term consequences
Interactions
- -May potentiate effects of myostatin inhibitors (e.g., follistatin, ACE-031) leading to unpredictable muscle remodeling outcomes
- -Potential additive suppression of erythropoiesis when combined with other TGF-beta pathway modulators or certain chemotherapeutic agents
- -May interact with exogenous growth hormone or IGF-1 therapies by opposing or modulating anabolic signaling in muscle tissue
- -Theoretical interaction with anticoagulants due to potential effects on vascular remodeling and endothelial function
- -May amplify effects of other SMAD2/3 pathway activators such as TGF-beta1 supplementation or activin A
Cost & Where to Buy
Research-grade lyophilized GDF-11 is sold by peptide vendors typically in 100-500mcg vials at $40-150 per vial; monthly cost depends heavily on dose and vendor purity. Purity and authenticity vary significantly between suppliers, and pharmaceutical-grade formulations do not exist commercially.
Search on Amazon